https://www.zacks.com/stock/news/2228151/roche-s-rhhby-xolair-gets-approval-for-food-allergies?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2228151
Feb 19, 2024 - Roche (RHHBY) obtains FDA approval for Xolair for the treatment of children and adults with one or more food allergies.
zc:2421545480960216920
0
https://www.zacks.com/stock/news/2236717/bayer-bayry-q4-earnings-top-crop-science-unit-drives-revenues?cid=CS-ZC-FT-analyst_blog|earnings_article-2236717
Mar 06, 2024 - Bayer (BAYRY) beats earnings estimates in the fourth quarter of 2023, primarily driven by increased sales of Crop Science and Pharmaceuticals products.
zc:4521125375410249720
0
https://www.zacks.com/stock/news/2239502/regeneron-regn-gets-fda-nod-for-praluent-label-extension?cid=CS-ZC-FT-analyst_blog|earnings_article-2239502
Mar 12, 2024 - Regeneron (REGN) obtains FDA approval for Praluent as an adjunct to diet and other LDL-C, lowering therapies to include pediatric patients aged eight and older with HeFH.
zc:-6107377359256798521
0
https://www.zacks.com/stock/news/2243015/intellia-ntla-begins-dosing-in-phase-iii-attr-amyloidosis-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2243015
Mar 19, 2024 - Intellia (NTLA) doses the first patient in the phase III MAGNITUDE study on NTLA-2001 for treating transthyretin amyloidosis with cardiomyopathy.
zc:-3316277904804375071
0
https://www.zacks.com/stock/news/2252785/exel-or-regn-which-is-the-better-value-stock-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-2252785
Apr 09, 2024 - EXEL vs. REGN: Which Stock Is the Better Value Option?
zc:-6254228627173850506
0
https://www.zacks.com/stock/news/2257012/2seventy-bio-tsvt-rises-more-than-50-in-3-months-here-s-why?cid=CS-ZC-FT-analyst_blog|price_surge_/_plunge-2257012
Apr 17, 2024 - The FDA's recent nod to 2seventy bio's (TSVT) Abecma in earlier lines of treatment for relapsed/refractory multiple myeloma is a positive. Also, the R&D asset divestiture to Regeneron is saving costs.
zc:-5865686420277375127
0
https://www.zacks.com/commentary/2261192/top-stock-reports-for-danaher-regeneron-pharmaceuticals-palo-alto-networks?cid=CS-ZC-FT-research_daily-2261192
Apr 24, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Danaher Corporation (DHR), Regeneron Pharmaceuticals, Inc. (REGN) and Palo Alto Networks, Inc. (PANW).
zc:817260156667333572
0
https://www.zacks.com/stock/news/2265330/will-these-5-drug-biotech-stocks-beat-q1-earnings-forecast?cid=CS-ZC-FT-analyst_blog|earnings_preview_-_esp-2265330
Apr 30, 2024 - Let's look at five large-cap pharma/biotech companies slated to release quarterly results this week.
zc:1590785385393557674
0
https://www.zacks.com/stock/news/2272320/intellia-s-ntla-q1-earnings-revenues-beat-estimates?cid=CS-ZC-FT-analyst_blog|earnings_article-2272320
May 10, 2024 - Intellia's (NTLA) earnings and revenues surpass estimates in the first quarter of 2024. The company provides developmental and regulatory updates on its pipeline candidates. Stock rises.
zc:-3113895207676113220
0
https://www.zacks.com/stock/news/2272917/sanofi-sny-regeneron-s-dupixent-sbla-gets-fda-priority-tag?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2272917
May 13, 2024 - Sanofi (SNY) and Regeneron's (REGN) Dupixent is poised to be the first medicine for adolescents with inadequately controlled CRSwNP, if approved by the FDA.
zc:-5109054605420823827
0